Phase
Condition
Urticaria
Allergy
Allergies & Asthma
Treatment
Biological NTLA-2002
Normal Saline IV Administration
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age >18 years
Diagnosis of HAE Types I or II
Ability to provide evidence of HAE attacks to meet the screening requirement
Subjects must have access to, and the ability to use, ≥ 1 acute medication(s) totreat angioedema attacks.
Adequate chemistry and hematology measures at screening
Subjects must agree not to participate in another interventional study for theduration of this trial.
Subjects must be capable of providing signed informed consent
Exclusion
Exclusion Criteria:
Concurrent diagnosis of any other type of recurrent angioedema
Subjects who have known negative reaction or hypersensitivity to any lipidnanoparticles (LNP) component.
Any condition that, in the Investigator's opinion, could adversely affect the safetyof the subject.
Unwilling to comply with study procedures.
Study Design
Connect with a study center
Clinical Trial Site
Campbelltown,
AustraliaSite Not Available
Clinical Trial Site
Grenoble,
FranceSite Not Available
Clinical Trial Site
Lille,
FranceSite Not Available
Clinical Trial Site
Paris,
FranceSite Not Available
Clinical Trial Site
Berlin,
GermanySite Not Available
Clinical Trial Site
Frankfurt,
GermanySite Not Available
Clinical Trial Site
Amsterdam,
NetherlandsSite Not Available
Clinical Trial Site
Auckland,
New ZealandSite Not Available
Clinical Trial Site
Cambridge,
United KingdomSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.